A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
一项 1 期随机、双盲、安慰剂对照、单剂量和多剂量递增研究，旨在评估 PF-06835375（一种靶向 CXC 趋化因子受体 5 型的抗体）在系统性红斑狼疮或类风湿性关节炎患者中的安全性和药代动力学/药效学。
期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-024-03337-2
Cohen, Stanley; Beebe, Jean S; Chindalore, Vishala; Guan, Shunjie; Hassan-Zahraee, Mina; Saxena, Madhurima; Xi, Li; Hyde, Craig; Koride, Sarita; Levin, Robert; Lubaczewski, Shannon; Salganik, Mikhail; Sloan, Abigail; Stevens, Erin; Peeva, Elena; Vincent, Michael S; Martin, David A; Chu, Myron
